Skip to main content
Journal cover image

Frailty in patients with ovarian cancer and the role of healthcare access, race, and ethnicity.

Publication ,  Journal Article
Meernik, C; Osazuwa-Peters, OL; Wilson, LE; Joshi, A; Pisu, M; Liang, MI; Ward, KC; Kuliszewski, MG; Tucker, T; Berchuck, A; Huang, B; Akinyemiju, T
Published in: Gynecol Oncol
August 29, 2024

OBJECTIVE: Ovarian cancer has poor 5-year survival, particularly among non-Hispanic (NH) Black patients. Efforts to identify patients at high-risk of functional limitations and frailty may improve outcomes. In this study, we examined how healthcare access (HCA) and race/ethnicity relate to frailty among patients with ovarian cancer. METHODS: We identified Hispanic, NH Black, and NH White patients diagnosed at ages ≥6 5 years with ovarian cancer between 2009 and 2015 using SEER-Medicare. Log-binomial regression was used to estimate prevalence ratios (PRs) and 95% confidence intervals (CIs) for the association between HCA and race/ethnicity with pre- or post-diagnosis frailty, adjusting for age and comorbidities. RESULTS: A total of 6041 patients with ovarian cancer were included, including 91.8% NH White, 6.6% NH Black, and 1.7% Hispanic. Pre-diagnosis, 14.7% of patients were defined as frail (NH White: 14.3%; NH Black: 17.9%; Hispanic: 20.8%). Post-diagnosis, frailty prevalence increased to 58.8% (NH White: 58.2%; NH Black: 65.2%; Hispanic: 70.2%). No statistically significant associations were observed between race/ethnicity and pre- or post-diagnosis frailty in fully adjusted models. After adjustment for patient characteristics and healthcare accessibility and availability, higher healthcare affordability was associated with a decreased prevalence of pre-diagnosis frailty (PR: 0.91, 95% CI: 0.8 5, 0.98). CONCLUSIONS: Patients with ovarian cancer have a high prevalence of frailty after diagnosis, particularly NH Black and Hispanic patients. Improving healthcare affordability may prevent or help manage frailty in Medicare patients, improve receipt of cancer treatment, and increase cancer survival.

Duke Scholars

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

August 29, 2024

Volume

190

Start / End Page

146 / 152

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3215 Reproductive medicine
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1114 Paediatrics and Reproductive Medicine
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Meernik, C., Osazuwa-Peters, O. L., Wilson, L. E., Joshi, A., Pisu, M., Liang, M. I., … Akinyemiju, T. (2024). Frailty in patients with ovarian cancer and the role of healthcare access, race, and ethnicity. Gynecol Oncol, 190, 146–152. https://doi.org/10.1016/j.ygyno.2024.08.017
Meernik, Clare, Oyomoare L. Osazuwa-Peters, Lauren E. Wilson, Ashwini Joshi, Maria Pisu, Margaret I. Liang, Kevin C. Ward, et al. “Frailty in patients with ovarian cancer and the role of healthcare access, race, and ethnicity.Gynecol Oncol 190 (August 29, 2024): 146–52. https://doi.org/10.1016/j.ygyno.2024.08.017.
Meernik C, Osazuwa-Peters OL, Wilson LE, Joshi A, Pisu M, Liang MI, et al. Frailty in patients with ovarian cancer and the role of healthcare access, race, and ethnicity. Gynecol Oncol. 2024 Aug 29;190:146–52.
Meernik, Clare, et al. “Frailty in patients with ovarian cancer and the role of healthcare access, race, and ethnicity.Gynecol Oncol, vol. 190, Aug. 2024, pp. 146–52. Pubmed, doi:10.1016/j.ygyno.2024.08.017.
Meernik C, Osazuwa-Peters OL, Wilson LE, Joshi A, Pisu M, Liang MI, Ward KC, Kuliszewski MG, Tucker T, Berchuck A, Huang B, Akinyemiju T. Frailty in patients with ovarian cancer and the role of healthcare access, race, and ethnicity. Gynecol Oncol. 2024 Aug 29;190:146–152.
Journal cover image

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

August 29, 2024

Volume

190

Start / End Page

146 / 152

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3215 Reproductive medicine
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1114 Paediatrics and Reproductive Medicine
  • 1112 Oncology and Carcinogenesis